P/E ratio for Gilead Sciences (GILD)
P/E ratio as of April 2024 (TTM): 15.3
According to Gilead Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 15.2506. At the end of 2022 the company had a P/E ratio of 23.4.
P/E ratio history for Gilead Sciences from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 23.4 | 59.47% |
| 2021 | 14.7 | -97.48% |
| 2020 | 583 | 3701.51% |
| 2019 | 15.3 | 2.96% |
| 2018 | 14.9 | -26.45% |
| 2017 | 20.2 | 184.87% |
| 2016 | 7.10 | -13.23% |
| 2015 | 8.19 | -30.86% |
| 2014 | 11.8 | -68.31% |
| 2013 | 37.4 | 73.46% |
| 2012 | 21.5 | 91.56% |
| 2011 | 11.2 | 4.87% |
| 2010 | 10.7 | -27.65% |
| 2009 | 14.8 | -37.99% |
| 2008 | 23.9 | -9.63% |
| 2007 | 26.4 | -206.29% |
| 2006 | -24.9 | -184.23% |
| 2005 | 29.5 | -12.22% |
| 2004 | 33.6 | -122.51% |
| 2003 | -149 | -262.62% |
| 2002 | 91.9 | -20.3% |
| 2001 | 115 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -30.58% | 🇺🇸 USA |
 Pfizer PFE | 14.1 | -7.42% | 🇺🇸 USA |
 AbbVie ABBV | 45.6 | 199.10% | 🇺🇸 USA |
 Eli Lilly LLY | 135 | 783.25% | 🇺🇸 USA |
 Amgen AMGN | 19.2 | 26.00% | 🇺🇸 USA |
 Biogen BIIB | 10.5 | -31.05% | 🇺🇸 USA |
 Illumina ILMN | -4.52 | -129.63% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 30.6 | 100.33% | 🇺🇸 USA |
 Merck MRK | 69.7 | 356.92% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.